Business Wire

NZMP: New Research Hopes to Unlock Understanding of How the Gut and Brain Interact

Del

NZMP SureStart™, the global B2B paediatric ingredients brand of Fonterra, announces today it is part of Smarter Lives, a five-year research programme to investigate how nutrition impacts the gut-brain axis.

Smarter Lives is funded by New Zealand’s Ministry of Business, Innovation and Employment and is led by New Zealand research institute, AgResearch. It will investigate how foods influence brain function via the sophisticated communication systems between the gut and the brain.

Fonterra’s Programme Manager Nutrition and Health, James Dekker, says, “The gut is sometimes referred to as ‘the second brain’, and the Smarter Lives research programme will help to explore what is meant by this.

There has been a significant amount of research into the role of dairy ingredients in cognition and gut health. However, more work is needed to understand the gut-brain axis and what this means for paediatric nutrition.

“For example, we know ingredients like NZMP SureStart™ Lipid 100 may offer both digestive health and cognition benefits, but we don’t fully understand how these two functions correlate.

“Another study has found levels of good gut bacteria were increased in formula fed infants consuming SureStart™ BifidoB 019, showing the ingredient’s effect on gut microbiota1. However, we don’t completely understand how ingredients like SureStart™ BifidoB 019 impact behaviours and cognition,” says James.

The research is supported by the Riddet Institute, the Centre for Brain Research and Fonterra Research and Development Centre, in collaboration with international researchers at Flinders University, Illinois University and University College Cork.

“We know the first years of a child’s life are a sensitive period during which the child’s brain is most receptive to the effects of nutrition and its environment. Both are vital for the optimal development of the brain.

“The Smarter Lives research programme will build on existing research and unlock how we can influence the two-way communication between the gut and the brain to help to optimise cognitive development in formula fed infants,” says James.

What is the Gut-Brain Axis?

There is a vast network of neurons, called the enteric nervous system, that line the gut. Research has found that a direct line of two way communication exists between the brain and the enteric nervous system. This means that influences on the gut and its functions, such as diet, can impact signals sent to the brain.

Breast milk is the ideal source of nutrition for infants. Breast milk is the best nutrition you can give to your baby. It’s full of everything a baby needs to grow and develop in a healthy way and gives children the very best start in life. Breast milk substitutes are recognised by the World Health Organisation as safe and nutritious alternatives to breast milk for infants whose mothers cannot, or choose not to, breastfeed.

1 Oswari H, Prayitno L, Dwipoerwantoro PG, et al. Comparison of stool microbiota compositions, stoppl alpha1-antitrypsin and calprotectin concentrations, and diarrhoeal morbidity of Indonesian infants fed breast milk or probiotic/prebiotic-supplemented formula. Journal of Paediatrics and Child Health (2013).

About Smarter Lives

NZ-based AgResearch scientists leading a research programme looking at the future of foods to boost the brain. More than $12 million has been awarded by the NZ Ministry of Business, Innovation and Employment's Endeavour Fund for this research.

The project is called 'Smarter Lives: New opportunities for dairy products across the lifespan', and is focused on how foods can influence brain performance via the ''gut-brain axis''. This research is undertaken in collaboration with Fonterra, the Riddet Institute, The University of Auckland's Centre for Brain Research, Australia's Flinders University, Ireland's University College Cork, and Illinois University in the United States.

About SureStart™

SureStart™ is NZMP’s paediatric ingredients brand. NZMP has a long heritage in paediatric innovation. Inspired by breast milk composition from the beginning, NZMP invests in world-leading research. This underpins SureStart™ ingredient innovation, and enables NZMP to be at the forefront of paediatric nutrition. SureStart™ focus areas are cognition, protection, digestive health and growth and development. Visit www.surestartnutrition.com for more information.

About NZMP

NZMP is the global dairy ingredients brand of Fonterra. Trusted globally, NZMP ingredients are sold in more than 130 countries and can be found at the heart of some of the world’s most famous food and nutrition brands. NZMP has one of the broadest ranges of ingredients in the dairy industry, providing hundreds of solutions to meet the needs of customers and consumers every day.

Backed by Fonterra, NZMP draws on New Zealand’s grass-fed farming heritage and expertise, world-class processing and leading quality standards. NZMP ingredients deliver a market advantage, trusted for their high performance and exceptional quality. www.nzmp.com

Contact information

For further information or to organise an interview contact:
Porter Novelli on behalf of NZMP
Adam Szentes, +64 21 265 1067
adams@porternovelli.kiwi

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues26.3.2019 06:00:00 CETPressemelding

Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/ Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team

Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA25.3.2019 23:00:00 CETPressemelding

Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W

Game of Thrones Winter is Coming™ Launches Worldwide25.3.2019 23:00:00 CETPressemelding

Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi

bluebird bio Statement on European Regulatory Status of LentiGlobin™25.3.2019 22:40:00 CETPressemelding

A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 20:30:00 CETPressemelding

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in

AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 19:50:00 CETPressemelding

Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin